Certara, Inc. Q1 FY2025 earnings

Certara closed the first quarter of fiscal 2025 with stronger profitability and cash flow. Revenue was $106.0 million, up 9.7% from the prior-year quarter. GAAP operating income was $7.6 million, a swing to a profit. Net income was $4.7 million, up 201% from a year-ago loss. Diluted EPS was $0.03, up from a year-ago loss. Operating margin was 7.2%, up 8.5 percentage points from a negative prior-year margin. The GAAP results include several non-cash and deal-related items. On a non-GAAP basis, adjusted EBITDA was $34.8 million, against $29.1 million a year earlier. Adjusted net income was $22.2 million, against $16.5 million. Adjusted diluted EPS was $0.14, against $0.10. The company excludes equity-based compensation, amortization of acquisition-related intangible assets, changes in contingent consideration, acquisition-related expenses, reorganization expense, loss on disposal of fixed assets, and executive recruiting expense from its adjusted figures.

Cash generation and backlog improved. Operating cash flow was $17.4 million, up 303.9% from the prior-year quarter. Capital expenditures were $0.6 million, down 3.1%. Deferred revenue was $73.3 million, up 25.9% from a year earlier. Remaining performance obligations were $139.2 million, up 20.6%. Bookings were $118.2 million, compared with $105.8 million a year earlier. Net retention rates were 102.4%, compared with 114.1%. Organic revenue was $100.1 million, representing 4% growth. The company said revenue growth came from technology-enabled services and software product offerings, helped by a business acquisition and expansion with existing customers. The company also said the increase in operating cash flow was driven by higher cash-adjusted net income, a decrease in accounts receivable, and lower cash outflows for prepaid and other assets.

Certara is a biosimulation and Model-Informed Drug Development company. It serves the biopharmaceutical industry with software and technology-enabled services. The company has completed 21 acquisitions since 2013, of which 14 included software or technology. It has worked with more than 2,400 life sciences companies and academic institutions and has collaborated on more than 9,000 customer projects in the last decade. Its software products are licensed by more than 94,000 users and are used by 23 global drug regulatory agencies, including the FDA and Japan’s Pharmaceuticals and Medical Devices Agency. Management believes more life science companies will use its end-to-end platform to cut costs and speed drugs to market.

Management expects headcount and total operating expenses to continue to increase over time. It plans to invest in scientific talent, sales and marketing, research and development, operational functions, and complementary businesses. It also expects income tax expense to increase as the company grows more profitable. A strategic review of the regulatory services business is under way and could lead to several outcomes that may significantly affect operations. The company sees regulatory acceptance of biosimulation as critical to demand for its products and services.

Risks are visible. The biosimulation market is competitive and highly fragmented. Regulatory policy changes could reduce demand. The new U.S. federal administration is focused on drug pricing and accelerated drug approval, which could create opportunities and challenges. A relaxation of regulatory requirements or streamlined approval procedures could hurt demand for regulatory services. Macroeconomic conditions, including inflation, interest rates, trade disputes, tariffs, changes in government funding, geopolitical conflicts, and pandemics, could pressure the business. Customer retention and bookings can vary significantly from quarter to quarter. The net retention rate was 102.4%, compared with 114.1% a year earlier. The ongoing review of the regulatory services business adds another layer of uncertainty.